Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease

Summary

The aim of this study is to assess the efficacy and safety of GSK4527226 in participants with early Alzheimer's Disease (AD) (including mild cognitive impairment \[MCI\] and mild dementia due to AD) of 2 dose levels of GSK4527226 compared to placebo.

Timeline

Start

2023-10-20

Primary completion

2026-09-30

Completion

2026-11-23

Drugs

Indications